Navigation Links
Mouse Adult Stem Cells Developed into Heart and Blood Cells
Date:4/30/2008

Key Step toward Clinical Testing of Stem Cells Developed from Patients'

Skin Cells

DURHAM, N.C., April 30 /PRNewswire/ -- Researchers have succeeded in inducing stem cells grown from mouse skin cells to differentiate into functioning cardiovascular and blood cells, according to a study publishing online tomorrow in the journal "Stem Cells."

(Logo: http://www.newscom.com/cgi-bin/prnh/20080422/CLTU133LOGO-a )

"Induced pluripotent stem (iPS) cells are reprogrammed cells obtained by genetic manipulation of normal adult cells that then express capabilities similar to embryonic stem cells," explains Dr. Miodrag Stojkovic, Co-Editor of "Stem Cells." "That is, iPS cells are theoretically able to differentiate into 220 different cell types. For the first time, scientists from UCLA were able to induce the differentiation of mouse iPS cells into functional heart cells, smooth muscle cells, and blood cells."

Katja Schenke-Layland and colleagues at UCLA performed a series of experiments using mouse iPS cells, using reprogrammed cells obtained from skin biopsies in adult mice. Although iPS cells are believed to be equivalent to embryonic stem cells, rigorous scientific studies are needed to confirm their potential to differentiate into specific types of cells.

Experiments in mice using iPS cells confirmed that the stem cells had differentiated into mature heart muscle cells (cardiomyocytes) and vascular smooth muscle cells (the specialized muscle cells lining the blood vessel walls). In addition, studies of cultured iPS cells showed markers characteristic of early cardiovascular and hematopoietic (blood-forming) cells. The iPS cells were essentially the same as mouse embryonic stem cells at the same stage of differentiation.

Using relatively simple laboratory techniques, the researchers were then able to induce iPS cells to develop into functional cardiomyocytes, smooth muscle cells, and hematopoietic cells. The functional cells showed only minor differences from cells developed from embryonic stem cells.

The ability to generate stem cells using the patient's own cells holds great promise for the treatment of currently incurable degenerative diseases, as well as for cell-based drug discovery. In recent months, reports from UCLA and other research groups have shown that human skin cells can be reprogrammed into cells that are nearly identical to human embryonic stem cells, without the need to use human embryos or eggs.

The new results are an important milestone, extensively documenting the capability of inducing mouse iPS cells to develop into different types of functional cells. The next step will be to develop efficient, reliable, and safe techniques of generating human cardiovascular and hematopoietic cells for use in testing new "patient-tailored regenerative therapies," the researchers write.

Dr. Stojkovic adds, "The development of functional cells from iPS is a key step forward in the development of patient-specific embryonic stem cells for use in developing new treatments for conditions such as Alzheimer's disease, Parkinson's disease, and spinal cord injury, among others."

The article, entitled "Reprogrammed Mouse Fibroblasts Differentiate into Cells of the Cardiovascular and Hematopoietic Lineages," will be available online May 1, 2008, at: http://www.stemcells.com/papbyrecent.dtl .

About AlphaMed Press

AlphaMed Press publishes the internationally renowned journals, "Stem Cells" and "The Oncologist." "Stem Cells," now in its 26th year, is the oldest and one of the world's top-tier peer-reviewed monthly journals in the fast-paced area of stem cells and regenerative medicine. "The Oncologist," in its 13th year, is a premier peer-reviewed monthly journal dedicated to physicians entrusted with the care of cancer patients. View AlphaMed Press journals at http://www.alphamedpress.org .

Contacts (please direct questions related to content to the corresponding author):
STEM CELLS' Editorial Office/Communications: Corresponding Author:

George Kendall, GKendall@alphamedpress.com W. Robb MacLellan,

Phone: 919-680-0011 (Ext. 224) rmaclellan@mednet.ucla.edu

Cardiovascular

STEM CELLS' Co-Editor: Research Laboratory,

Professor Miodrag Stojkovic, University of California

mstojkovic@cipf.es Los Angeles School

Phone: +381 63 768 6185 of Medicine

Phone: 310-825-2556


'/>"/>
SOURCE AlphaMed Press
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Mature Mouse Cells Reprogrammed to Stem Cell-Like State
2. Boston College biologists build a better mouse model for cancer research
3. Mouse model for mesothelioma reproduces human disease
4. Mouse study: Real-time imaging device may improve surgery for congenital colon disease
5. Seal Shield Introduces New Silver Seal Washable, Antimicrobial Mouse at HiMSS Healthcare Symposium
6. Mouse Model of Age-Related Macular Degeneration Developed
7. Gene Tweak Reverses Aging in Mouse Skin Cells
8. A longer-living, healthier mouse that could hold clues to human aging
9. Mouse mammary tumor virus can replicate in human cells
10. Mouse Study Gives Clues to Colitis
11. Mouse vision has a rhythm all its own
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/4/2016)... ... December 03, 2016 , ... The Lymphoma Research Foundation ... research and serving the lymphoma community through a comprehensive series of education programs, ... Event in New York City, with long-time partners The Paul Foundation, on November ...
(Date:12/4/2016)... Aliso Viejo, California (PRWEB) , ... December 04, ... ... self-animating lower third presets that have new attractive animation styles with unique displacement ... Pro3rd Displace features 30 pre-animated lower third designs. Choose from a variety of ...
(Date:12/2/2016)... , ... December 02, 2016 , ... Lori G. ... Traurig, LLP’s Atlanta office, will speak at the American Conference Institute’s 21st Drug ... Traurig is also a Lead Sponsor of the conference. , Cohen, who chairs the ...
(Date:12/2/2016)... ... December 02, 2016 , ... Advanced Inc., a leading provider of ... Bice, CPA, MBA to serve as Advanced Inc.’s Chief Financial Officer, effective December 1, ... Jason brings extensive financial and operational leadership experience to Advanced Inc. He began his ...
(Date:12/2/2016)... PA (PRWEB) , ... December 02, 2016 , ... With ... struggling through rehabilitation of an injury, patients must find the one that works for ... his pain, he created a machine that worked and decided to share it with ...
Breaking Medicine News(10 mins):
(Date:12/4/2016)...   Pairnomix, LLC, a genetic research company and ... the White House, today announced that findings from its first ... candidate therapies for a patient with epileptic encephalopathy caused by ... at the 70 th Annual Meeting of the ... , December 2-6, 2016.  Pairnomix, unique process involves ...
(Date:12/4/2016)... EAST HANOVER, N.J. , Dec. 3, 2016 /PRNewswire/ ... SEG101 (crizanlizumab, formerly SelG1), an anti-P-selectin antibody, reduced the ... by 45.3% compared to placebo (1.63 vs 2.98, p=0.010) ... Novartis today announced that the data are being featured ... American Society of Hematology (ASH) Annual Meeting and ...
(Date:12/4/2016)... Dec. 3, 2016  Findings from a Novartis ... CTL019, an investigational chimeric antigen receptor T cell ... young adult patients with B-cell acute lymphoblastic leukemia ... session at the 58th American Society of Hematology ... p.m.). The global Phase II study found that ...
Breaking Medicine Technology: